Georgi Dinkov AKA Haidut on Vaccines, mRNA therapies, Genetics, Transhumanism, Metaverse, Cancer Stocks, Big Pharma/Tech, Coffee, Metabolic Diseases, Stress and Fatigue.
1)Have you been watching $NVAX since the interview and if, what do you think about it? Seems heavily shorted in the last 14 days, and although they haven't actually delivered any serious numbers (but are on track to very shortly, they partnered with Serum Institute of India, a largest vaccine manufacturer in the world), the price does seem low looking at the previous levels. I am not speaking from health perspective around vaccines but solely as an investment into the stock.
2)When's the part 2 coming out? Great interview! Am a long time fan of his work and intellect.
All I saw was that $NVAX is extremely volatile. Price did not manage to increase after the EU approved the vaccine, which must be disheartening for shareholders. It is possible that the stock is pricing in expectations of the pandemic ending. I have no insights into Novavax.
Very interesting!
I just do not understand regarding serotonin and depression... isn't most of the antidepressants based on increasing the amount of in the brain?
Yes 🤯 read this https://raypeat.com/articles/articles/serotonin-depression-aggression.shtml
1)Have you been watching $NVAX since the interview and if, what do you think about it? Seems heavily shorted in the last 14 days, and although they haven't actually delivered any serious numbers (but are on track to very shortly, they partnered with Serum Institute of India, a largest vaccine manufacturer in the world), the price does seem low looking at the previous levels. I am not speaking from health perspective around vaccines but solely as an investment into the stock.
2)When's the part 2 coming out? Great interview! Am a long time fan of his work and intellect.
We do not have a part 2 planned yet but all in good time! Yes, Georgi is on another level.
All I saw was that $NVAX is extremely volatile. Price did not manage to increase after the EU approved the vaccine, which must be disheartening for shareholders. It is possible that the stock is pricing in expectations of the pandemic ending. I have no insights into Novavax.